WO2002016555A3 - Htert-immortalised cell lines, their preparation and use - Google Patents

Htert-immortalised cell lines, their preparation and use Download PDF

Info

Publication number
WO2002016555A3
WO2002016555A3 PCT/GB2001/003726 GB0103726W WO0216555A3 WO 2002016555 A3 WO2002016555 A3 WO 2002016555A3 GB 0103726 W GB0103726 W GB 0103726W WO 0216555 A3 WO0216555 A3 WO 0216555A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell lines
htert
cells
transfected
immortalised
Prior art date
Application number
PCT/GB2001/003726
Other languages
French (fr)
Other versions
WO2002016555A2 (en
Inventor
Christopher John Jones
David Glyn Kipling
Gavin Wilkinson
Brian Mcsharry
Julia Wendy Skinner
Original Assignee
Univ Wales Medicine
Christopher John Jones
David Glyn Kipling
Gavin Wilkinson
Brian Mcsharry
Julia Wendy Skinner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020246A external-priority patent/GB0020246D0/en
Application filed by Univ Wales Medicine, Christopher John Jones, David Glyn Kipling, Gavin Wilkinson, Brian Mcsharry, Julia Wendy Skinner filed Critical Univ Wales Medicine
Priority to AU2001282290A priority Critical patent/AU2001282290A1/en
Publication of WO2002016555A2 publication Critical patent/WO2002016555A2/en
Publication of WO2002016555A3 publication Critical patent/WO2002016555A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

An immortalised cell line is disclosed, which is suitable for use in vaccine production, characterised in that the cells thereof are adapted to express hTERT, the catalytic subunit of human telomerase. A suitable cell line comprises human diploid fibroblasts, such as those derivable from MRC-5 or WI38 cell lines, transfected with cDNA of hTERT or infected by a retrovirus carrying cDNA of hTERT, which transfected or infected cells are capable of supporting antigen production. A method for preparing such cell lines, using recombinant techniques, is also disclosed. The cell lines may be used as a diagnostic test for the presence of a virus, such as HCMV. Alternatively, the telomerase-immortalised cell lines may be used to determine the efficacy of anti-viral agents by testing the capability of a modified virus, such as HCMV containing a reporter gene, to infect these cells.
PCT/GB2001/003726 2000-08-17 2001-08-17 Htert-immortalised cell lines, their preparation and use WO2002016555A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001282290A AU2001282290A1 (en) 2000-08-17 2001-08-17 Htert-immortalised cell lines, their preparation and use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22573400P 2000-08-17 2000-08-17
US60/225,734 2000-08-17
GB0020246.5 2000-08-17
GB0020246A GB0020246D0 (en) 2000-08-17 2000-08-17 Cell lines

Publications (2)

Publication Number Publication Date
WO2002016555A2 WO2002016555A2 (en) 2002-02-28
WO2002016555A3 true WO2002016555A3 (en) 2002-10-17

Family

ID=26244847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003726 WO2002016555A2 (en) 2000-08-17 2001-08-17 Htert-immortalised cell lines, their preparation and use

Country Status (2)

Country Link
AU (1) AU2001282290A1 (en)
WO (1) WO2002016555A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321978D0 (en) * 2003-09-19 2003-10-22 Integrin Advanced Biosystems L New method of producing cell cultures
US9453209B2 (en) 2012-12-27 2016-09-27 Sierra Sciences, Llc Enhancing health in mammals using telomerase reverse transcriptase gene therapy
PT3405212T (en) 2016-01-19 2020-08-25 Pfizer Cancer vaccines
US20220387516A1 (en) * 2019-11-02 2022-12-08 Figene, Llc Fibroblast-derived universal immunological composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
WO2001036651A1 (en) * 1999-11-19 2001-05-25 Cantab Pharmaceuticals Research Limited Preparation of human or animal herpesviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
WO2001036651A1 (en) * 1999-11-19 2001-05-25 Cantab Pharmaceuticals Research Limited Preparation of human or animal herpesviruses

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BODNAR ANDREA G ET AL: "Extension of life-span by introduction of telomerase into normal human cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, no. 5349, 16 January 1998 (1998-01-16), pages 349 - 352, XP002157587, ISSN: 0036-8075 *
BRESNAHAN WADE A ET AL: "Replication of wild-type and mutant human cytomegalovirus in life-extended human diploid fibroblasts", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 22, November 2000 (2000-11-01), pages 10816 - 10818, XP002163581, ISSN: 0022-538X *
FRANCO S ET AL: "Clonal variation in phenotype and life span of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT).", EXPERIMENTAL CELL RESEARCH, vol. 268, no. 1, 1 August 2001 (2001-08-01), pages 14 - 25, XP002188247, ISSN: 0014-4827 *
FRANCO SONIA ET AL: "Expression of telomerase after retroviral transduction increases lifespan of primary human fibroblasts.", PEDIATRIC RESEARCH, vol. 45, no. 4 PART 2, April 1999 (1999-04-01), Annual Meeting of the American Pediatric Society and the Society for Pediatric Research;San Francisco, California, USA; May 1-4, 1999, pages 146A, XP001027601, ISSN: 0031-3998 *
JIANG XU-RONG ET AL: "Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 21, no. 1, January 1999 (1999-01-01), pages 111 - 114, XP002144961, ISSN: 1061-4036 *
MACKENZIE KAREN L ET AL: "Mass cultured fibroblasts overexpressing hTERT from a retroviral vector enter crisis following an extended period of proliferation.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 226, XP001026310, ISSN: 0197-016X *
MACKENZIE KAREN L ET AL: "Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation.", EXPERIMENTAL CELL RESEARCH, vol. 259, no. 2, 15 September 2000 (2000-09-15), pages 336 - 350, XP002188248, ISSN: 0014-4827 *
MCSHARRY B P ET AL: "Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus.", JOURNAL OF GENERAL VIROLOGY, vol. 82, no. 4, April 2001 (2001-04-01), pages 855 - 863, XP001027071, ISSN: 0022-1317 *
NAKAYAMA JUN-ICHI ET AL: "Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.", NATURE GENETICS, vol. 18, no. 1, January 1998 (1998-01-01), pages 65 - 68, XP001027528, ISSN: 1061-4036 *
OH SANGTAEK ET AL: "Identification of Mad as a repressor of the human telomerase (hTERT) gene.", ONCOGENE, vol. 19, no. 11, 9 March 2000 (2000-03-09), pages 1485 - 1490, XP001027580, ISSN: 0950-9232 *
TAHARA HIDETOSHI ET AL: "Possible role of loss of p16 in the immortalization of human cells with telomerase catalytic subunit of telomerase (hTERT).", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 225, XP001026311, ISSN: 0197-016X *
WEN JIANPING ET AL: "Reconstitution of wild-type or mutant telomerase activity in telomerase-negative immortal human cells.", HUMAN MOLECULAR GENETICS, vol. 7, no. 7, July 1998 (1998-07-01), pages 1137 - 1141, XP001027557, ISSN: 0964-6906 *
WYLLIE F S ET AL: "Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts.", NATURE GENETICS, (2000 JAN) 24 (1) 16-7., XP002188246 *

Also Published As

Publication number Publication date
WO2002016555A2 (en) 2002-02-28
AU2001282290A1 (en) 2002-03-04

Similar Documents

Publication Publication Date Title
Chi et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice
Rodrigues et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology
ES2536745T3 (en) Methods of production of influenza vaccine compositions
ES2009350A6 (en) Expression and purification of an HTLV-III gag/env gene protein
ES2716010T3 (en) Methods and compositions for cytomegalovirus IL-10 protein
WO2006031264A3 (en) Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
ATE527281T1 (en) VACCINES AGAINST AIDS COMPRISING CMV/R NUCLEIC ACID CONSTRUCTS
BR9814606A (en) Vaccine formulation and methods of treating an individual infected with an hpv virus and preventing papillomavirus infection
WO2002022080A3 (en) Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
WO2006004661A1 (en) Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
WO2000053729A3 (en) Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
HUP0202826A2 (en) Novel composition
Sharpe et al. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses
Perez et al. A single dose of an MVA vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein neutralizes variants of concern and protects mice from a lethal SARS-CoV-2 infection
ES8706208A1 (en) Expression of immunologically reactive viral proteins.
Wang et al. Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice
Zhao et al. Co-immunization with CHIKV VLP and DNA vaccines induces a promising humoral response in mice
HUP0105392A2 (en) Enhanced vaccines
WO2002004007A3 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
WO2002016555A3 (en) Htert-immortalised cell lines, their preparation and use
WO2003040305A3 (en) Porcine adenovirus e1 and e4 regions
WO1999053047A3 (en) Porcine adenovirus type 3 genome
Khattar et al. Enhanced immune responses to HIV-1 envelope elicited by a vaccine regimen consisting of priming with Newcastle disease virus expressing HIV gp160 and boosting with gp120 and SOSIP gp140 proteins
Robertson An overview of host cell selection.
Homan et al. Further studies of naturally occurring latent bovine herpesvirus infection.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP